Search - tctmd.com

Displaying 121 - 140 of 190

Sort: Relevancy | Date

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Shelley Wood

April 18, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

Shelley Wood

April 02, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

Presentation Controversies and Advances 2017

PCSK9 Inhibitors - Are They Worth The Money?

Presenter: Michael J. Blaha

November 16, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Presentation TCT 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presenter: Gregg W. Stone, Peter H. Stone, Evan A. Stein

November 01, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

Advertisement

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

Alirocumab Price Slashed in Deal With Express Scripts

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

TCTMD’s Top 10 Most Popular Stories for March 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

The Biggest News of 2017: TCTMD’s Top 10

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

PCSK9 Inhibitors - Are They Worth The Money?

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Evolocumab Not Cost-Effective at Current List Price

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

TCTMD’s Top 10 Most Popular Stories for May 2017

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content